Vivesto AB (OTCPK:OASMY)
$ 0.0499 0 (0%) Market Cap: 8.95 Mil Enterprise Value: 3.84 Mil PE Ratio: 0 PB Ratio: 0.87 GF Score: 33/100

Oasmia Pharmaceutical AB (publ) - Special Call Transcript

Mar 01, 2021 / 01:00PM GMT
Release Date Price: $1.15
Francois R. Martelet;publ;CEO;
Oasmia Pharmaceutical AB

()-

Thank you, and good afternoon, everyone. I'm very pleased to hear that we have over 100 participants on this webcast. So really thank you for that. So this morning, we announced the acquisition of Global development and commercialization rights for Cantrixil, a clinical stage ovarian cancer program, building, therefore, critical mass in our oncology pipeline. Over the course of the next hour or so, I'm looking forward to sharing with you the strategic rationale for this move and our excitement about it as we believe it marks an important milestone in Oasmia transformation. And as usual, we will be hosting a Q&A session at the end of this presentation.

Slide 2, that I will not ask you to read. Slide 3. So today, I am joined by Dr. Reinhard Koenig, who is our acting Chief Scientific Officer, who has been working for quite some time for Oasmia. And since this is the first time that you hear Reinhard, I would kindly ask him to present himself in a few words. Reinhard, the floor is yours.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot